Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11422710 | 0.80 | NPC1 (0.46) | HRASTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL10392563 | 0.77 | HRAS (0.42) | HRASTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL9408911 | 0.77 | HRAS (0.42) | HRASTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL3930158 | 0.77 | HRAS (0.49) | HRASTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL326199 | 0.75 | RAB9A (0.54) | GAANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL9100722 | 0.75 | TSHR (0.46) | HRASTSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL206646 | 0.74 | HRAS (0.65) | HRASTSHRNPC1RAB9AKDM4E | |
| SCHEMBL1983662 | 0.72 | HRAS (0.49) | HRASTSHRGAANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL6967279 | 0.72 | HRAS (0.62) | HRASTSHRGAANPC1RAB9A | |
| SCHEMBL10776729 | 0.72 | HRAS (0.68) | HRASTSHRGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970154-B1 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS | US HEALTH (US) | 2021-07-07 | — | — | EP | disclosed |
| US-10137212-B2 | Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-27 | — | — | US | disclosed |
| US-20160022844-A1 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS | The USA, as represented by the secretary, Department of Health & Human Service (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2970154-A1 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164988-A1 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-1212301-A1 | ARYLALKYLOXYALKYLAMINES AND ARYLALKYLTHIOALKYLAMINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016107-A1 | ARYLALKYLOXYALKYLAMINES AND ARYLALKYLTHIOALKYLAMINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022844-A1 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS | SLC39A3, SLC39A11, SLC39A7 | HRAS 3761/4885TSHR 87/4885GAA 855/4885 |
| US-10137212-B2 | Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications | SLC39A3, SLC39A11, SLC39A7 | HRAS 3761/4885TSHR 87/4885GAA 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.